Medical drug program updates
You can refer to the chart below to review changes and updates related to CarePartners of Connecticut's prior authorization and coverage program for medical drugs.
Medications being added to prior authorization | ||
Drug(s) | Effective date | Policy & additional information |
Rytelo (imetelstat) | 1/1/2025 | Prior authorization will be required for Rytelo (HCPCS C9399, J3490), approved by the FDA in April 2024 for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. |
Botulinum Toxins
| 2/1/2025 | |
Leqvio (inclisiran) | 2/1/2025 | |
Spravato (esketamine) | 2/1/2025 | |